Bayer Launches Phase III Clinical Study of Trasylol in Elective Spinal Fusion Surgery

Size: px
Start display at page:

Download "Bayer Launches Phase III Clinical Study of Trasylol in Elective Spinal Fusion Surgery"

Transcription

1 Investor News Bayer AG Investor Relations Leverkusen Germany Bayer Launches Phase III Clinical Study of Trasylol in Elective Spinal Fusion Surgery Study Examines Effects of Trasylol in Reducing Bleeding and Need for Blood Transfusions for Spinal Fusion Patients Leverkusen / December 8, 2005 Bayer Pharmaceuticals Corporation (NYSE: BAY) today announced the initiation of a Phase III clinical trial to evaluate the safety and efficacy of Trasylol (aprotinin injection) in reducing blood loss and the need for transfusion in adult patients undergoing elective spinal fusion surgery. Spinal fusion surgery involves fusing together one or more of the small bones of the spine with bone grafts and devices. This fusion limits the motion between the vertebrae allowing surgeons to treat injuries to the spine, repair broken vertebra, correct deformities, adjust abnormal curvatures, stabilize weakness and remedy slipped or herniated disks. Approximately 300,000 spinal fusion surgeries take place each year in the United States, a figure that has doubled in the last decade. i Patients undergoing spinal fusion surgery are subject to a blood transfusion rate that may be six times greater than that of patients undergoing spinal surgery without fusion. ii Spine fusion surgery is also associated with more complications (such as infection, chronic pain and neural injuries) as it requires more extensive dissection and longer operative time. iii Blood loss can be a significant complication of spine surgery. Combined with the potential health risks associated with transfusions and the rising cost of blood products, there is a great need to reduce bleeding in this surgical setting, said Michael Neuwirth, MD, lead investigator of the study and director of the Spine Institute at Beth Israel Medical Center. Trasylol has been proven safe and effective in reducing blood - 2 -

2 - 2 - loss and transfusion requirements in coronary artery bypass surgery, and we are studying the drug to determine if it may play a similar role in spinal fusion surgery. The multi-center, randomized, double-blind, placebo-controlled trial will assess the ability of Trasylol to reduce bleeding and the need for blood transfusions in elective spinal fusion surgery involving three to seven vertebral levels. Over 450 adult patients will be randomly assigned to receive 200 ml of intravenous Trasylol or placebo at the start of the operation, followed by 50 ml/hour of either agent until the surgery is complete. Close to 40 investigational centers in North America will participate in the study. Trasylol is currently approved for use in more than 60 countries. In the United States, Trasylol is indicated for prophylactic use to reduce perioperative blood loss and the need for blood transfusion in patients undergoing cardiopulmonary bypass (CPB) in the course of coronary artery bypass graft (CABG) surgery. Studies have continued to provide evidence supporting the hemostatic effects of Trasylol in orthopedic surgery, said Dr. Paul MacCarthy, Vice President of Medical Affairs at Bayer. We are hopeful that this clinical trial will validate those findings and establish the safety and efficacy of Trasylol therapy in the setting of spinal fusion surgery. In April 2005, Bayer had announced the initiation of a Phase III study to evaluate the safety and efficacy of Trasylol in reducing blood loss and the need for transfusion in patients undergoing elective primary total hip replacement surgery. Previous Study Results A recent evidence-based review of previously published prospective, randomized studies evaluating aprotinin therapy in spine surgery demonstrated a significant reduction in blood loss and the amount of blood transfused. iv Approximately 200 adult patients undergoing spinal fusion have been included in previous Bayer sponsored and independently published controlled studies with v, vi, vii Trasylol. In these trials, the incidence of adverse events was comparable to placebo, including the occurrence of deep vein thrombosis. For additional safety information associated with the use of Trasylol, see Important Safety Considerations below

3 - 3 - About Spinal Fusion Spinal fusion is a surgical technique in which one or more of the vertebrae of the spine are united together so that motion no longer occurs between them. Bone grafts are placed around the spine during surgery, and the body then heals the grafts over several months, joining the vertebrae together. The ultimate goal of spinal fusion is to obtain a solid union between two or more vertebrae. The procedure may involve use of supplemental hardware (instrumentation) such as plates, screws and cages. Instrumentation is sometimes used to correct a deformity, but usually is just used as an internal splint to hold the vertebrae together while the bone grafts heal. The immediate discomfort following spinal fusion is generally greater than with other types of spinal surgeries. Patients typically stay in the hospital for three or four days; however, a longer stay after more extensive surgery is not uncommon. A short stay in a rehabilitation unit after release from the hospital is often recommended for patients who had extensive surgery, or for elderly or debilitated patients. viii About Trasylol Trasylol, a broad-spectrum proteinase inhibitor, modulates the systemic inflammatory response associated with cardiopulmonary bypass (CPB) in the course of CABG surgery. Approved by the FDA in 1993, Trasylol is the only product indicated for prophylactic use to reduce perioperative blood loss and the need for blood transfusion in patients undergoing CPB in the course of CABG surgery. Full prescribing and warning information is also available at ix The effects of Trasylol use in CPB involves a reduction of inflammatory response to surgery, reduced bleeding and decreased re-exploration for bleeding, which translates into a decreased need for allogeneic (blood donated from another individual) blood transfusions. An important part of Bayer Pharmaceuticals Corporation s Specialty Pharmaceuticals portfolio, Trasylol has remained a category leader for several years. Bayer is committed to further investment in the Trasylol franchise and is actively engaged in the research and development of a recombinant version of the product. In anticipation of emerging needs of this market, Bayer is also leading in next generation product development

4 - 4 - Important Safety Considerations Anaphylactic or anaphylactoid reactions are possible when Trasylol is administered. Hypersensitivity reactions are rare in patients with no prior exposure to aprotinin. The risk of anaphylaxis is increased in patients who are reexposed to aprotinin-containing products. The benefit of Trasylol to patients undergoing primary CABG surgery should be weighed against the risk of anaphylaxis should a second exposure to aprotinin be required (see WARNINGS and PRECAUTIONS in the Trasylol prescribing information). In clinical studies, hypersensitivity and anaphylactic reactions were: rare (<0.1%) in patients with no prior exposure to Trasylol 2.7% overall reaction rate upon re-exposure o within 6 months, the incidence was 5 percent o after 6 months, the incidence was 0.9 percent Trasylol is generally well tolerated. In clinical trials, graft patency, myocardial infarction, renal or hepatic dysfunction and mortality were comparable to placebo. About Bayer Pharmaceuticals Corporation Bayer Pharmaceuticals Corporation ( is part of the worldwide operations of Bayer HealthCare AG, a subsidiary of Bayer AG. Bayer HealthCare, with sales of approximately 8.5 billion Euro in 2004, is one of the world's leading, innovative companies in the health care and medical products industry. The company combines the global activities of the divisions: Animal Health, Biological Products, Consumer Care, Diagnostics and Pharmaceuticals. Bayer HealthCare employed 35,300 people worldwide in Bayer HealthCare's aim is to discover and manufacture innovative products that will improve human and animal health worldwide. Our products enhance well-being and quality of life by diagnosing, preventing and treating disease. Leverkusen, December 8,

5 - 5 - Bayer AG, Investor Relations contacts: Dr. Alexander Rosar ( ) Dr. Juergen Beunink ( ) Peter Dahlhoff ( ) Ilia Kürten ( ) Ute Menke ( ) Judith Nestmann ( ) Forward-looking statements This news release contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in our public reports filed with the Frankfurt Stock Exchange and with the U.S. Securities and Exchange Commission (including our Form 20-F). The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. i Agency for Healthcare Research and Quality. Healthcare Cost and Utilization Project, HCUPnet. Accessed on November 9, Available at: ii Deyo RA, et al. Lumbar spinal fusion: a cohort study of complications, reoperations, and resource use in the Medicare population. Spine 1993;18: iii Ibid. iv Kokoszka A, et al. Evidence-based review of the role of aprotinin in blood conservation during orthopaedic surgery. J Bone Joint Surg Am 2005;87: v Lentschener, C., et al. Reduction of blood loss and transfusion requirement by aprotinin in posterior lumbar spine fusion. Anesth Analg 89: 590-7, vi Urban, MK., et al. The efficacy of antifibrinolytics in the reduction of blood loss during complex adult reconstructive spine surgery. Spine 2001; 26(10): vii Bayer, S. A parallel, randomized double-blind, placebo controlled evaluation of the influence of high dose aprotinin in spinal fusion surgery on intra-operative blood loss. Report No. PH31776/1; viii North American Spine Society. Spinal Fusion Surgery. What is it? How is it done? Accessed on October 11, Available at: ix Trasylol Prescribing Information. Accessed on November 15, Available at:

Phase II Data Presented as Late-Breaker at American Heart Association Meeting Phase III Study to be Initiated in December 2008

Phase II Data Presented as Late-Breaker at American Heart Association Meeting Phase III Study to be Initiated in December 2008 Investor News Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Secondary Prevention in Acute Coronary Syndrome (ACS): Bayer s Xarelto Shows Encouraging Results in Patients with

More information

Bayer s Xarelto (Rivaroxaban) Meets Primary Efficacy Endpoint and Shows Significant Reduction in Mortality in Major ACS Study

Bayer s Xarelto (Rivaroxaban) Meets Primary Efficacy Endpoint and Shows Significant Reduction in Mortality in Major ACS Study Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Secondary Prevention of Acute Coronary Syndrome (ACS): Bayer s Xarelto (Rivaroxaban)

More information

Bayer AG Investor Relations Leverkusen Germany Investor News. Not intended for U.S. and UK Media

Bayer AG Investor Relations Leverkusen Germany   Investor News. Not intended for U.S. and UK Media Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer Initiates Xarelto (Rivaroxaban) Study in Patients with Non- Valvular Atrial

More information

Supplemental New Drug Application for Rivaroxaban to reduce the risk of stent thrombosis in patients with Acute Coronary Syndrome also resubmitted

Supplemental New Drug Application for Rivaroxaban to reduce the risk of stent thrombosis in patients with Acute Coronary Syndrome also resubmitted Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Complete Response Submitted to U.S. FDA on Bayer s Rivaroxaban for the Reduction

More information

Nexavar in Combination with Chemotherapy Demonstrates 74 Percent Improvement in Progression-Free Survival

Nexavar in Combination with Chemotherapy Demonstrates 74 Percent Improvement in Progression-Free Survival Investor News Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Phase II Study in Advanced Breast Cancer: Nexavar in Combination with Chemotherapy Demonstrates 74 Percent Improvement

More information

Bayer and Regeneron start additional Phase 3 Study for VEGF Trap-Eye in Wet Age-related Macular Degeneration

Bayer and Regeneron start additional Phase 3 Study for VEGF Trap-Eye in Wet Age-related Macular Degeneration Investor News Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer and Regeneron start additional Phase 3 Study for VEGF Trap-Eye in Wet Age-related Macular Degeneration International

More information

VEGF Trap-Eye: New Data Confirm Successes in the Treatment of Age-related Macular Degeneration

VEGF Trap-Eye: New Data Confirm Successes in the Treatment of Age-related Macular Degeneration Investor News Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Final Phase 2 Results Presented at Retina Society Meeting VEGF Trap-Eye: New Data Confirm Successes in the Treatment

More information

New Data Reaffirm Positive Benefit-Risk Balance of Bayer s Xarelto in Patients with Atrial Fibrillation in Daily Clinical Practice

New Data Reaffirm Positive Benefit-Risk Balance of Bayer s Xarelto in Patients with Atrial Fibrillation in Daily Clinical Practice Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com 12 th Annual Congress of the European Cardiac Arrhythmia Society (ECAS) 2016:

More information

New Study Presented at American Heart Association (AHA) Scientific Sessions 2016:

New Study Presented at American Heart Association (AHA) Scientific Sessions 2016: Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com New Study Presented at American Heart Association (AHA) Scientific Sessions

More information

Rivaroxaban 10 mg Once Daily from Bayer Submitted to U.S. FDA as Additional Dose Option to Reduce the Risk of Recurrent Venous Thromboembolism

Rivaroxaban 10 mg Once Daily from Bayer Submitted to U.S. FDA as Additional Dose Option to Reduce the Risk of Recurrent Venous Thromboembolism Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Rivaroxaban 10 mg Once Daily from Bayer Submitted to U.S. FDA as Additional

More information

Bayer s rivaroxaban submitted to U.S. FDA for approval in patients with coronary and/or peripheral artery disease

Bayer s rivaroxaban submitted to U.S. FDA for approval in patients with coronary and/or peripheral artery disease Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer s rivaroxaban submitted to U.S. FDA for approval in patients with coronary

More information

Bayer and Regeneron start clinical Phase III trial to extend ophthalmology research & development program for VEGF Trap- Eye in Asia

Bayer and Regeneron start clinical Phase III trial to extend ophthalmology research & development program for VEGF Trap- Eye in Asia Investor News Not intended for U.S. Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com VEGF Trap-Eye in myopic choroidal neovascularization: Bayer and Regeneron start clinical

More information

Bayer submits application for marketing approval of rivaroxaban for patients with coronary or peripheral artery disease to European Medicines Agency

Bayer submits application for marketing approval of rivaroxaban for patients with coronary or peripheral artery disease to European Medicines Agency Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer submits application for marketing approval of rivaroxaban for patients

More information

Bayer and Loxo Oncology to develop and commercialize two novel oncology therapies selectively targeting genetic drivers of cancer

Bayer and Loxo Oncology to develop and commercialize two novel oncology therapies selectively targeting genetic drivers of cancer Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer and Loxo Oncology to develop and commercialize two novel oncology therapies

More information

Treatment of visual impairment due to macular edema secondary to branch retinal vein occlusion (BRVO):

Treatment of visual impairment due to macular edema secondary to branch retinal vein occlusion (BRVO): Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Treatment of visual impairment due to macular edema secondary to branch retinal

More information

Spinal Fusion. North American Spine Society Public Education Series

Spinal Fusion. North American Spine Society Public Education Series Spinal Fusion North American Spine Society Public Education Series What Is Spinal Fusion? The spine is made up of a series of bones called vertebrae ; between each vertebra are strong connective tissues

More information

Start of Phase IIIb Study with Bayer s Riociguat in PAH Patients Who Demonstrate an Insufficient Response to PDE-5 Inhibitors

Start of Phase IIIb Study with Bayer s Riociguat in PAH Patients Who Demonstrate an Insufficient Response to PDE-5 Inhibitors Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Pulmonary Arterial Hypertension (PAH): Start of Phase IIIb Study with Bayer

More information

Bayer s Rivaroxaban Demonstrated Superior Protection Against Recurrent Venous Thromboembolism Compared with Aspirin in EINSTEIN CHOICE Study

Bayer s Rivaroxaban Demonstrated Superior Protection Against Recurrent Venous Thromboembolism Compared with Aspirin in EINSTEIN CHOICE Study News Release Not intended for U.S. and UK Media Bayer AG Communications and Public Affairs 51368 Leverkusen Germany Tel. +49 214 30-0 www.news.bayer.com New Late-Breaking Study Data Presented at ACC.17:

More information

Bayer Pharma AG Berlin Germany Tel News Release. Not intended for U.S. and UK Media

Bayer Pharma AG Berlin Germany Tel News Release. Not intended for U.S. and UK Media News Release Not intended for U.S. and UK Media Bayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com Landmark Phase III Study of Bayer s Xarelto (Rivaroxaban) Initiated for the

More information

News Release. For UK Media

News Release. For UK Media News Release For UK Media Bayer plc 400 South Oak Way Reading RG2 6AD www.bayer.co.uk Bayer s Xarelto (rivaroxaban) in combination with single antiplatelet therapy receives positive CHMP opinion for treatment

More information

Bayer to showcase latest Ophthalmology research at EURETINA 2017

Bayer to showcase latest Ophthalmology research at EURETINA 2017 Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com 17 th European Society of Retina Specialists (EURETINA) Congress Bayer to showcase

More information

Bayer to Present New Data on Advancing Oncology Portfolio. New Preclinical and Early Clinical Data Evaluating Innovative Compounds in Drug Development

Bayer to Present New Data on Advancing Oncology Portfolio. New Preclinical and Early Clinical Data Evaluating Innovative Compounds in Drug Development Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com 105 th Annual Meeting American Association for Cancer Research Bayer to Present

More information

PIONEER AF-PCI Study with Bayer s Xarelto Accepted as Late- Breaking Clinical Trial Presentation at AHA 2016

PIONEER AF-PCI Study with Bayer s Xarelto Accepted as Late- Breaking Clinical Trial Presentation at AHA 2016 News Release Not intended for U.S. and UK Media Bayer AG Communications, Government Relations & Corporate Brand 51368 Leverkusen Germany Tel. +49 214 30-0 www.news.bayer.com American Heart Association

More information

University of Pennsylvania Health System Aprotinin Task Force

University of Pennsylvania Health System Aprotinin Task Force Aprotinin Use in Adult Cardiac Surgery: A Recommendation Statement from the University of Pennsylvania Health System Center for Evidence-based Practice *Note: This guideline was originally released on

More information

- May Help Increase Appropriate Early Use in Acute Coronary Syndrome Patients -

- May Help Increase Appropriate Early Use in Acute Coronary Syndrome Patients - MEDIA INVESTORS Ken Dominski John Elicker Bristol-Myers Squibb Bristol-Myers Squibb 609-252-5251 212-546-3775 ken.dominski@bms.com john.elicker@bms.com Amy Ba Felix Lauscher sanofi-aventis sanofi-aventis

More information

Posterior. Lumbar Fusion. Disclaimer. Integrated web marketing. Multimedia Health Education

Posterior. Lumbar Fusion. Disclaimer. Integrated web marketing. Multimedia Health Education Posterior Lumbar Fusion Disclaimer This movie is an educational resource only and should not be used to make a decision on. All decisions about surgery must be made in conjunction with your surgeon or

More information

American College of Cardiology 66th Annual Scientific Session (ACC.17):

American College of Cardiology 66th Annual Scientific Session (ACC.17): News Release Not intended for U.S. and UK Media Bayer AG Communications and Public Affairs 51368 Leverkusen Germany Tel. +49 214 30-0 www.news.bayer.com American College of Cardiology 66th Annual Scientific

More information

Iroko Pharmaceuticals Announces Acceptance for Filing of ZORVOLEX snda for the Treatment of Osteoarthritis Pain in Adults

Iroko Pharmaceuticals Announces Acceptance for Filing of ZORVOLEX snda for the Treatment of Osteoarthritis Pain in Adults Iroko Pharmaceuticals Announces Acceptance for Filing of ZORVOLEX snda for the Treatment of Osteoarthritis Pain in Adults First Lower Dose NSAID Using SoluMatrix Fine Particle Technology to be Reviewed

More information

Daiichi Sankyo and Lilly Receive U.S. FDA Approval for Effient

Daiichi Sankyo and Lilly Receive U.S. FDA Approval for Effient For Immediate Release Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Takashi Shoda, President and Representative Director (Code no.: 4568, First Section, Tokyo, Osaka and Nagoya Stock Exchanges)

More information

Landmark Phase III Study of Bayer s Xarelto (Rivaroxaban) Initiated for the Secondary Prevention of Myo

Landmark Phase III Study of Bayer s Xarelto (Rivaroxaban) Initiated for the Secondary Prevention of Myo Xarelto (Rivaroxaban) Landmark Phase III Study of Bayer s Xarelto (Rivaroxaban) Initiated for the Secondary Prevention of Myocardial Infarction and Death in Patients with Coronary or Peripheral Artery

More information

SPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS

SPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS SPHERIX Investor Relations Phone: (301) 897-2564 Email: info@spherix.com SPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS BETHESDA, MD, May 21, 2010 - Spherix Incorporated (NASDAQ CM: SPEX), an innovator

More information

NEWS RELEASE Media Contact: Krysta Pellegrino (650) Investor Contact: Sue Morris (650) Advocacy Contact: Kristin Reed (650)

NEWS RELEASE Media Contact: Krysta Pellegrino (650) Investor Contact: Sue Morris (650) Advocacy Contact: Kristin Reed (650) NEWS RELEASE Media Contact: Krysta Pellegrino (650) 225-8226 Investor Contact: Sue Morris (650) 225-6523 Advocacy Contact: Kristin Reed (650) 467-9831 FDA APPROVES AVASTIN IN COMBINATION WITH CHEMOTHERAPY

More information

MINNEAPOLIS September 12, 2012 Medtronic, Inc. (NYSE: MDT) today announced findings

MINNEAPOLIS September 12, 2012 Medtronic, Inc. (NYSE: MDT) today announced findings NEWS RELEASE Contacts: Wendy Dougherty Jeff Warren Public Relations Investor Relations 707-541-3004 763-505-2696 FOR IMMEDIATE RELEASE HEALTH-ECONOMIC ANALYSIS SUGGESTS MEDTRONIC SYMPLICITY RENAL DENERVATION

More information

Another Record Year for Bayer HealthCare Pharmaceuticals in Asia Pacific

Another Record Year for Bayer HealthCare Pharmaceuticals in Asia Pacific News Release Bayer (South East Asia) Pte Ltd Communications 63 Chulia Street OCBC Centre East, 14 th Floor Singapore 049514 Tel. +65 6496 1888 Co. No.: 197901344Z Another Record Year for Bayer HealthCare

More information

Regorafenib from Bayer Submitted to Health Authorities Seeking Approval in Second-Line Treatment of Liver Cancer

Regorafenib from Bayer Submitted to Health Authorities Seeking Approval in Second-Line Treatment of Liver Cancer News Release Not intended for U.S. and UK Media Bayer AG Communications, Government Relations & Corporate Brand 51368 Leverkusen Germany Tel. +49 214 30-0 www.news.bayer.com Regorafenib from Bayer Submitted

More information

NEWS RELEASE Media Contact: Megan Pace Investor Contact: Kathee Littrell Patient Inquiries: Ajanta Horan

NEWS RELEASE Media Contact: Megan Pace Investor Contact: Kathee Littrell Patient Inquiries: Ajanta Horan NEWS RELEASE Media Contact: Megan Pace 650-467-7334 Investor Contact: Kathee Littrell 650-225-1034 Patient Inquiries: Ajanta Horan 650-467-1741 GENENTECH RECEIVES COMPLETE RESPONSE LETTER FROM FDA FOR

More information

First Albany Orthopedics Conference Marina Village, San Diego February 13, 2007 Orthofix International

First Albany Orthopedics Conference Marina Village, San Diego February 13, 2007 Orthofix International First Albany Orthopedics Conference Marina Village, San Diego February 13, 2007 Orthofix International Tom Hein, CFO Safe Harbor Statement Except for historical information contained herein, the statements

More information

AVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer

AVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer FOR IMMEDIATE RELEASE AVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer Study designed to build upon safety profile demonstrated

More information

(direct) (609) (mobile)

(direct) (609) (mobile) MEDIA Sanofi-aventis Bristol-Myers Squibb Ingrid Görg-Armbrecht Laura Hortas + 33 153-774-625 (direct) (609) 252-4587 +33 686-056-688 (mobile) laura.hortas@bms.com ingrid.goerg-armbrecht@sanofi-aventis.com

More information

GIAPREZA (angiotensin II) Update

GIAPREZA (angiotensin II) Update Corporate Presentation GIAPREZA (angiotensin II) Update NASDAQ: LJPC December 2017 0 Forward Looking Statement These slides contain forward-looking statements as that term is defined in the Private Securities

More information

OTEZLA (Apremilast) Showed Meaningful Improvements in Clinical and Quality of Life Measures of Psoriasis Beyond Those Captured by Assessing Skin Alone

OTEZLA (Apremilast) Showed Meaningful Improvements in Clinical and Quality of Life Measures of Psoriasis Beyond Those Captured by Assessing Skin Alone OTEZLA (Apremilast) Showed Meaningful Improvements in Clinical and Quality of Life Measures of Psoriasis Beyond Those Captured by Assessing Skin Alone Patients with moderate to severe plaque psoriasis

More information

TIVORBEX Now Available in U.S. Pharmacies for the Treatment of Acute Pain

TIVORBEX Now Available in U.S. Pharmacies for the Treatment of Acute Pain TIVORBEX Now Available in U.S. Pharmacies for the Treatment of Acute Pain Second Low-Dose SoluMatrix NSAID from Iroko Now Available by Prescription PHILADELPHIA, June 29, 2015 Iroko Pharmaceuticals, LLC,

More information

Consumer Care A Strong Foundation in Consumer Health

Consumer Care A Strong Foundation in Consumer Health Consumer Care A Strong Foundation in Consumer Health Spring Investors Conference 2004 Leverkusen, March 19, 2004 Gary S. Balkema President Consumer Care Division Safe Harbor This presentation contains

More information

Galvus US NDA Approvable - Overview

Galvus US NDA Approvable - Overview Galvus US NDA Approvable - Overview Galvus NDA filed with FDA Jan 2006 PDUFA action date extended by 3 months until February 26th 2007 Significant new clinical data added to NDA - Approximately 1000 patient

More information

M (SAPPHIRE-II)

M (SAPPHIRE-II) PRESS RELEASE AbbVie Demonstrates 96 percent SVR 12 in its Phase III Study of Treatment- Experienced Patients with Genotype 1 Hepatitis C Results further confirm phase II studies, with consistent virologic

More information

Future Leaders in the Biotech Industry. Lee Bendekgey, SVP, CFO & General Counsel April 7, 2005

Future Leaders in the Biotech Industry. Lee Bendekgey, SVP, CFO & General Counsel April 7, 2005 Future Leaders in the Biotech Industry Lee Bendekgey, SVP, CFO & General Counsel April 7, 2005 Safe Harbor This presentation contains "forward-looking statements" regarding potential use of Nuvelo clinical

More information

About X-Linked Hypophosphatemia (XLH)

About X-Linked Hypophosphatemia (XLH) Ultragenyx and Kyowa Kirin Announce Publication of Phase 2 Study Results Demonstrating that Crysvita (burosumab) Improved Outcomes in Children with X-linked Hypophosphatemia in the New England Journal

More information

- Plans Commercial Launch of three dosing options for Excellagen in pre-filled syringes

- Plans Commercial Launch of three dosing options for Excellagen in pre-filled syringes Generex Biotechnology Subsidiary Olaregen Therapeutix Inc. Plans Launch of FDA Cleared Excellagen Wound Conforming Gel Matrix with Three Dosage Options - Plans Commercial Launch of three dosing options

More information

2006 Annual Report. Anastomosis Made Simple

2006 Annual Report. Anastomosis Made Simple 2006 Annual Report R Anastomosis Made Simple Cardica designs and manufactures proprietary automated anastomosis systems used by surgeons to perform rapid, reliable and consistent connections, or anastomoses,

More information

Media Contacts: Kelley Dougherty Investor Contact: Graeme Bell (215) (908)

Media Contacts: Kelley Dougherty Investor Contact: Graeme Bell (215) (908) News Release Media Contacts: Kelley Dougherty Investor Contact: Graeme Bell (215) 652-0059 (908) 423-5185 Janet Skidmore (267) 305-7715 Merck Launches National Advertising Campaign for GARDASIL, Merck's

More information

AVEO and Astellas Report Final Overall Survival Results from TIVO-1

AVEO and Astellas Report Final Overall Survival Results from TIVO-1 AVEO and Astellas Report Final Overall Survival Results from TIVO-1 - Median Overall Survival of 28.8 Months Reported for Tivozanib in Patients with Advanced Kidney Cancer - CAMBRIDGE, Mass. and TOKYO,

More information

Noven Receives FDA Approval of a New Indication with a New Dose for Minivelle (Estradiol Transdermal System)

Noven Receives FDA Approval of a New Indication with a New Dose for Minivelle (Estradiol Transdermal System) Noven Receives FDA Approval of a New Indication with a New Dose for Minivelle (Estradiol Transdermal System) Minivelle now approved for prevention of postmenopausal osteoporosis at all doses New 0.025

More information

Introduction Posterior cervical fusion is done through the back posterior of the neck. The surgery joins two or more neck vertebrae into one solid section of bone. The medical term for fusion is arthrodesis.

More information

Iroko Pharmaceuticals Receives FDA Approval for VIVLODEX - First Low Dose SoluMatrix Meloxicam for Osteoarthritis Pain

Iroko Pharmaceuticals Receives FDA Approval for VIVLODEX - First Low Dose SoluMatrix Meloxicam for Osteoarthritis Pain Iroko Pharmaceuticals Receives FDA Approval for VIVLODEX - First Low Dose SoluMatrix Meloxicam for Osteoarthritis Pain VIVLODEX Developed to Align with FDA NSAID Recommendations Proven Efficacy at Low

More information

Forward-looking Statement Disclaimer

Forward-looking Statement Disclaimer Forward-looking Statement Disclaimer This presentation may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to

More information

U.S. MARKET FOR MINIMALLY INVASIVE SPINAL IMPLANTS

U.S. MARKET FOR MINIMALLY INVASIVE SPINAL IMPLANTS U.S. MARKET FOR MINIMALLY INVASIVE SPINAL IMPLANTS idata_usmis15_rpt Published in December 2014 By idata Research Inc., 2014 idata Research Inc. Suite 308 4211 Kingsway Burnaby, British Columbia, Canada,

More information

Head-to-Head Study Showed Prasugrel Statistically Superior to Clopidogrel in Reducing Recurrent Cardiovascular Events

Head-to-Head Study Showed Prasugrel Statistically Superior to Clopidogrel in Reducing Recurrent Cardiovascular Events Date: August 21, 2008 Refer to: Carole Copeland (OUS) Eli Lilly and Company 317-277-3661 (office) 317-610-6196 (cell) Tammy Hull (U.S.A.) Eli Lilly and Company 317-651-9116 (office) 317-614-5132 (cell)

More information

Savient's Pegloticase Data in Treatment-Failure Gout Patients Presented at 72nd Annual Meeting of the American College of Rheumatology Conference

Savient's Pegloticase Data in Treatment-Failure Gout Patients Presented at 72nd Annual Meeting of the American College of Rheumatology Conference Savient's Pegloticase Data in Treatment-Failure Gout Patients Presented at 72nd Annual Meeting of the American College of Rheumatology Conference EAST BRUNSWICK, N.J., Oct 27, 2008 /PRNewswire-FirstCall

More information

PATENCY-1 Top-Line Results

PATENCY-1 Top-Line Results PATENCY-1 Top-Line Results December 13, 2016 2016 Proteon Therapeutics, Inc. Cautionary Note Regarding Forward-Looking Statements This presentation contains statements that are, or may be deemed to be,

More information

FDA APPROVES EXPANDED USE OF LAP-BAND ADJUSTABLE GASTRIC BANDING SYSTEM FOR OBESE ADULTS

FDA APPROVES EXPANDED USE OF LAP-BAND ADJUSTABLE GASTRIC BANDING SYSTEM FOR OBESE ADULTS FDA APPROVES EXPANDED USE OF LAP-BAND ADJUSTABLE GASTRIC BANDING SYSTEM FOR OBESE ADULTS Obese Adults with a BMI of 30-40 with at Least One Obesity Related Comorbid Condition Now Qualify for LAP-BAND System

More information

AVEO Oncology Announces Strategic Restructuring. AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET

AVEO Oncology Announces Strategic Restructuring. AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET NEWS RELEASE FOR IMMEDIATE RELEASE AVEO Oncology Announces Strategic Restructuring AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET CAMBRIDGE, Mass., June 4, 2013 AVEO Oncology (NASDAQ: AVEO)

More information

COAGULATION, BLEEDING, AND TRANSFUSION IN URGENT AND EMERGENCY CORONARY SURGERY

COAGULATION, BLEEDING, AND TRANSFUSION IN URGENT AND EMERGENCY CORONARY SURGERY COAGULATION, BLEEDING, AND TRANSFUSION IN URGENT AND EMERGENCY CORONARY SURGERY VALTER CASATI, M.D. DIVISION OF CARDIOVASCULAR ANESTHESIA AND INTENSIVE CARE CLINICA S. GAUDENZIO NOVARA (ITALY) ANTIPLATELET

More information

Avenue Therapeutics, Inc. August 2016

Avenue Therapeutics, Inc. August 2016 Avenue Therapeutics, Inc. August 2016 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward looking statements within the meaning of the safe

More information

Preoperative anemia Common, consequential and correctable in non-emergent surgery By Kathrine Frey, MD

Preoperative anemia Common, consequential and correctable in non-emergent surgery By Kathrine Frey, MD Preoperative anemia Common, consequential and correctable in non-emergent surgery By Kathrine Frey, MD Preoperative anemia is common, especially in patients undergoing nonemergent high-blood-loss surgical

More information

Marc A. Cohen, MD, FAAOS, FACS Diplomate American Board of Spinal Surgery Fellow American College of Spinal Surgery

Marc A. Cohen, MD, FAAOS, FACS Diplomate American Board of Spinal Surgery Fellow American College of Spinal Surgery Marc A. Cohen, MD, FAAOS, FACS Diplomate American Board of Spinal Surgery Fellow American College of Spinal Surgery 221 Madison Ave Morristown, New Jersey 07960 (973) 538 4444 Fax (973) 538 0420 Patient

More information

- Amendment accelerates anticipated PROSPER top-line results by two years -

- Amendment accelerates anticipated PROSPER top-line results by two years - Pfizer Contacts: For Media Dean Mastrojohn (212) 733-6944 dean.mastrojohn@pfizer.com For Investors Ryan Crowe (212) 733-8160 ryan.crowe@pfizer.com Astellas Contact: For Media Tyler Marciniak (847) 736-7145

More information

(908) (908)

(908) (908) Contact: Robert J. Hugin Brian P. Gill Senior VP and CFO Director, PR/IR Celgene Corporation Celgene Corporation (908) 673-9102 (908) 673-9530 REVLIMID (lenalidomide) SIGNIFICANTLY DELAYS TIME TO DISEASE

More information

News Release - 1/5 - Bayer Yakuhin, Ltd. Santen Pharmaceutical Co., Ltd.

News Release - 1/5 - Bayer Yakuhin, Ltd. Santen Pharmaceutical Co., Ltd. News Release Bayer Yakuhin, Ltd. Santen Pharmaceutical Co., Ltd. Intravitreal VEGF Inhibitor EYLEA (aflibercept) Solution for Intravitreal Injection Released on the Market for the Treatment of Wet Age-Related

More information

Avenue Therapeutics, Inc. September 2016

Avenue Therapeutics, Inc. September 2016 Avenue Therapeutics, Inc. September 2016 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward looking statements within the meaning of the

More information

Treatment Patterns and Outcomes in Metastatic Neuroendocrine Tumors: Results From a Retrospective Community Oncology Database

Treatment Patterns and Outcomes in Metastatic Neuroendocrine Tumors: Results From a Retrospective Community Oncology Database Ipsen Announces Eight Studies of Somatuline Depot (lanreotide) in Gastroenteropancreatic Neuroendocrine Tumors Being Presented at the North American Neuroendocrine Tumor Society (NANETS) Symposium Basking

More information

AVENUE THERAPEUTICS, INC. NASDAQ: ATXI JANUARY 2018

AVENUE THERAPEUTICS, INC. NASDAQ: ATXI JANUARY 2018 AVENUE THERAPEUTICS, INC. NASDAQ: ATXI JANUARY 2018 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward-looking statements within the meaning

More information

Company presentation. VFB Happening 16 April 2016

Company presentation. VFB Happening 16 April 2016 Company presentation VFB Happening 16 April 2016 FORWARD-LOOKING STATEMENTS This document and the accompanying oral presentation contain information on Bone Therapeutics SA markets and competitive position,

More information

February 23, Q4 and Year-End 2016 Financial Results

February 23, Q4 and Year-End 2016 Financial Results February 23, 2017 Q4 and Year-End 2016 Financial Results 2 RETHINKING CNS Agenda Today s Speakers Paul Cox, Senior Director, Investor Relations Jeff Jonas, M.D., Chief Executive Officer Jim Doherty, Ph.D.,

More information

Postpartum depression is the most common medical complication of childbirth, estimated to affect approximately 400,000 women annually in the U.S.

Postpartum depression is the most common medical complication of childbirth, estimated to affect approximately 400,000 women annually in the U.S. Sage Therapeutics Announces FDA Approval of ZULRESSO (brexanolone) Injection, the First and Only Treatment Specifically Indicated for Postpartum Depression March 19, 2019 Approval based on results from

More information

Novartis announces Phase III STRIVE data published in NEJM demonstrating significant and sustained efficacy of erenumab in migraine prevention

Novartis announces Phase III STRIVE data published in NEJM demonstrating significant and sustained efficacy of erenumab in migraine prevention Novartis International AG Novartis Global Communications CH-4002 Basel Switzerland http://www.novartis.com MEDIA RELEASE COMMUNIQUE AUX MEDIAS MEDIENMITTEILUNG Novartis announces Phase III STRIVE data

More information

Building a Stroke Portfolio. June 28, 2018

Building a Stroke Portfolio. June 28, 2018 Building a Stroke Portfolio June 28, 2018 1 Forward-Looking Statements This presentation contains forward-looking statements, including statements relating to: the potential benefits, safety and efficacy

More information

Daiichi Sankyo s Once-Daily Lixiana

Daiichi Sankyo s Once-Daily Lixiana Daiichi Sankyo s Once-Daily Lixiana (edoxaban) Receives Positive CHMP Opinion for the Prevention of Stroke and Systemic Embolism in Non-Valvular Atrial Fibrillation and for the Treatment and Prevention

More information

HTX-011 Postoperative Pain Program Topline Results from Phase 2b Studies. June 21, 2018

HTX-011 Postoperative Pain Program Topline Results from Phase 2b Studies. June 21, 2018 HTX-011 Postoperative Pain Program Topline Results from Phase 2b Studies June 21, 2018 Forward-Looking Statements This presentation contains "forward-looking statements" as defined by the Private Securities

More information

Robotic Spine Surgery [TASE]: MZOR

Robotic Spine Surgery [TASE]: MZOR Robotic Spine Surgery [TASE]: MZOR Nov. 2012 Forward Looking Statements Any forecast and/or forecasting statement, included in this presentation, is based on the Management's assessment at its discretion.

More information

Novartis receives FDA approval of Menveo, a vaccine to prevent meningococcal disease

Novartis receives FDA approval of Menveo, a vaccine to prevent meningococcal disease Novartis Vaccines and Diagnostics, Inc 350 Massachusetts Avenue Cambridge, MA 02139 http://www.novartisvaccines.com MEDIA RELEASE MEDIA RELEASE MEDIA RELEASE Novartis receives FDA approval of Menveo, a

More information

(212) Investors Contact: Ryan Crowe (212)

(212) Investors Contact: Ryan Crowe (212) For immediate release: February 5, 2014 Media Contact: Sally Beatty (212) 733-6566 Investors Contact: Ryan Crowe (212) 733-8160 Pfizer And Merck To Collaborate On Innovative Anti-Cancer Combination Studies

More information

Results Confirm and Extend 40-Week Findings that Treatment with Crysvita is Superior to Conventional Therapy

Results Confirm and Extend 40-Week Findings that Treatment with Crysvita is Superior to Conventional Therapy Ultragenyx and Kyowa Kirin Announce Positive 64-Week Results for Crysvita (burosumab) from Phase 3 Study in Children with X-linked Hypophosphatemia (XLH) Results Confirm and Extend 40-Week Findings that

More information

Investor Conference Call

Investor Conference Call Investor Conference Call Data from the Phase III COMPASS trial, A Randomized Controlled Trial of Rivaroxaban for the Prevention of Major Cardiovascular Events in Patients With Coronary or Peripheral Artery

More information

Phase 3 Top-Line Results Show IBRANCE in Combination with Fulvestrant Meets Progression-Free Survival (PFS) Primary Endpoint

Phase 3 Top-Line Results Show IBRANCE in Combination with Fulvestrant Meets Progression-Free Survival (PFS) Primary Endpoint For immediate release: April 15, 2015 Media Contact: Sally Beatty (212) 733-6566 Investor Contact: Ryan Crowe (212) 733-8160 Pfizer Announces PALOMA-3 Trial for IBRANCE (Palbociclib) Stopped Early Due

More information

AVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC

AVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC FOR IMMEDIATE RELEASE AVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC - Tivozanib is the First Agent to Demonstrate Greater than One Year

More information

Integra. Thumb Joint Replacement PATIENT INFORMATION. with PyroCarbon implants

Integra. Thumb Joint Replacement PATIENT INFORMATION. with PyroCarbon implants Integra Thumb Joint Replacement with PyroCarbon implants PATIENT INFORMATION Anatomy of the Hand The hand is composed of many different bones, muscles and ligaments that allow for a large amount of movement

More information

Rev (10/2014) VMA: A New Standard in Spine Diagnostic Imaging

Rev (10/2014) VMA: A New Standard in Spine Diagnostic Imaging Rev. 1038-1.1 (10/2014) VMA: A New Standard in Spine Diagnostic Imaging Spine Surgeons Lack Reliable Function Tests Critical to Other Surgeons Functional Tests Used to Select Surgery Patients Non-Specific

More information

Synergy Pharmaceuticals TRULANCE (Plecanatide) Receives U.S. FDA Approval for the Treatment of Adults with Chronic Idiopathic Constipation

Synergy Pharmaceuticals TRULANCE (Plecanatide) Receives U.S. FDA Approval for the Treatment of Adults with Chronic Idiopathic Constipation January 19, 2017 Synergy Pharmaceuticals TRULANCE (Plecanatide) Receives U.S. FDA Approval for the Treatment of Adults with Chronic Idiopathic Constipation NEW YORK--(BUSINESS WIRE)-- Synergy Pharmaceuticals

More information

Press Release. RedHill Biopharma Announces Enrollment of Last Patient in the BEKINDA Phase II Study for IBS-D

Press Release. RedHill Biopharma Announces Enrollment of Last Patient in the BEKINDA Phase II Study for IBS-D Press Release RedHill Biopharma Announces Enrollment of Last Patient in the BEKINDA Phase II Study for IBS-D Top-line results are expected in the third quarter of 2017 The randomized, double-blind, placebo-controlled

More information

Conventional therapy n=32. RGI-C Score (Primary Endpoint) LS Mean* (0.83, 1.45) P< Substantial healing, % patients (RGI-C +2.

Conventional therapy n=32. RGI-C Score (Primary Endpoint) LS Mean* (0.83, 1.45) P< Substantial healing, % patients (RGI-C +2. Ultragenyx and Kyowa Kirin Announce Topline Phase 3 Study Results Demonstrating Superiority of Crysvita (burosumab) Treatment to Oral Phosphate and Active Vitamin D in Children with X-Linked Hypophosphatemia

More information

Results from Hokusai-VTE presented during ESC Congress 2013 Hot Line session and published in the New England Journal of Medicine

Results from Hokusai-VTE presented during ESC Congress 2013 Hot Line session and published in the New England Journal of Medicine Press Release Daiichi Sankyo s Once-Daily Edoxaban Shows Comparable Efficacy and Superiority for the Principal Safety Endpoint Compared to Warfarin in a Phase 3 Study for the Treatment of Symptomatic VTE

More information

GUIDELINES FOR PATIENTS HAVING CERVICAL DISCECTOMY AND FUSION SURGERY

GUIDELINES FOR PATIENTS HAVING CERVICAL DISCECTOMY AND FUSION SURGERY ORTHOPAEDIC UNIT: 01-293 8687 /01-293 6602 UPMC BEACON CENTRE FOR ORTHOPAEDICS: 01-2937575 PHYSIOTHERAPY DEPARTMENT: 01-2936692 GUIDELINES FOR PATIENTS HAVING CERVICAL DISCECTOMY AND FUSION SURGERY Please

More information

REVLIMID IN COMBINATION WITH DEXAMETHASONE snda GRANTED APPROVAL BY FDA FOR TREATMENT OF MULTIPLE MYELOMA

REVLIMID IN COMBINATION WITH DEXAMETHASONE snda GRANTED APPROVAL BY FDA FOR TREATMENT OF MULTIPLE MYELOMA Contact: Robert J. Hugin Brian P. Gill President and COO Senior Director, PR/IR Celgene Corporation Celgene Corporation (908) 673-9102 (908) 673-9530 REVLIMID IN COMBINATION WITH DEXAMETHASONE snda GRANTED

More information

Package leaflet: Information for the patient. Trasylol 10,000 KIU/ml solution for injection or infusion. Aprotinin

Package leaflet: Information for the patient. Trasylol 10,000 KIU/ml solution for injection or infusion. Aprotinin Package leaflet: Information for the patient Trasylol 10,000 KIU/ml solution for injection or infusion Aprotinin Read all of this leaflet carefully before you are given this medicine because it contains

More information

Solutions For The Aging Spine

Solutions For The Aging Spine Solutions For The Aging Spine NASDAQ: ATEC February 2009 www.alphatecspine.com Slide 0 5818 El Camino Real, Carlsbad, CA 92008 www.alphatecspine.com Forward Looking Statements This presentation and our

More information

BRAINLAB ORTHOPEDICS SOFTWARE SOLUTIONS TO IMPROVE PATIENT CARE

BRAINLAB ORTHOPEDICS SOFTWARE SOLUTIONS TO IMPROVE PATIENT CARE BRAINLAB ORTHOPEDICS SOFTWARE SOLUTIONS TO IMPROVE PATIENT CARE BUZZ Buzz, the digital O.R. from Brainlab, is the clever central multi-touch information hub that routes, displays, interacts, streams, records,

More information

BioMarin Pharmaceutical Inc. Conference Call to Discuss Approval of

BioMarin Pharmaceutical Inc. Conference Call to Discuss Approval of BioMarin Pharmaceutical Inc. Conference Call to Discuss Approval of For adult patients with PKU who have uncontrolled blood phenylalanine (Phe) concentrations > 600 µmol/l on existing management May 24,

More information

US FDA Approves Pradaxa (dabigatran etexilate) a breakthrough treatment for stroke risk reduction in non-valvular atrial fibrillation

US FDA Approves Pradaxa (dabigatran etexilate) a breakthrough treatment for stroke risk reduction in non-valvular atrial fibrillation Press Release For non-us Healthcare Media Boehringer Ingelheim GmbH Corporate Communications US FDA Approves Pradaxa (dabigatran etexilate) a breakthrough treatment for stroke risk reduction in non-valvular

More information

WARNING: RISK OF SERIOUS DEHYDRATION IN PEDIATRIC PATIENTS

WARNING: RISK OF SERIOUS DEHYDRATION IN PEDIATRIC PATIENTS June 5, 2018 Synergy Pharmaceuticals Highlights New Data at Digestive Disease Week (DDW) 2018 Linking Uroguanylin Deficiency to Chronic Idiopathic Constipation (CIC) and Irritable Bowel Syndrome with Constipation

More information